BJUI. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer
|
|
- Philippa Gray
- 5 years ago
- Views:
Transcription
1 BJUI BJU INTERNATIONAL Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer Hamed Ahmadi, Anirban P. Mitra *, George A. Abdelsayed, Jie Cai, Hooman Djaladat, Harman M. Bruins and Siamak Daneshmand USC Institute of Urology, USC/Norris Comprehensive Cancer Center and * USC Department of Pathology and Center for Personalized Medicine, University of Southern California, Los Angeles, CA, USA Accepted for publication 11 July 2012 OBJECTIVE To develop a model that integrates the clinical and pathological information prior to radical cystectomy to increase the accuracy of current clinical stage in prediction of pathological stage in patients with bladder cancer (BC) using a modelling approach called principal component analysis (PCA). PATIENTS AND METHODS In a single-centre retrospective study, demographic and clinicopathological information of 1186 patients with clinically organ-confined (OC) BC was reviewed. Putative predictors of post-cystectomy pathological stage were identified using a stepwise logistic regression model. Patients were randomly divided into training data set (two-thirds of the study population, 790 patients) and test data set (one-third of the study population, 396 patients). The PCA method was used to develop the model in the training data set and the cut-off point (PCA score) to differentiate pathological OC disease from extravesical disease was determined. The model was then applied to the test data set without recalculation. What s known on the subject? and What does the study add? Clinical stage is an integral part of outlining treatment strategy and counselling patients with bladder cancer. The discordance rate between clinical stage and pathological stage, however, is currently high with more than 40% of patients with presumed organ-confined disease being upstaged after surgery. It accounts for the major part of overall pathological upstaging in patients with bladder cancer and is strongly associated with poor prognosis. There is an absolute need for additional methods to improve the accuracy of pre-surgical staging to predict post-surgical pathological stage of invasive bladder cancer for more accurate risk stratification. This study presents an internally validated pre-cystectomy principal component analysis staging model involving clinicopathological information on a large cohort of patients to predict post-surgical stage of bladder cancer. This model greatly reduces pathological upstaging to extravesical disease compared with clinical staging alone. RESULTS In all, 685 patients (57.7%) had pathological OC disease. Age, clinical stage, number of intravesical treatments, lymphovascular invasion, multiplicity of tumours, hydronephrosis and palpable mass were incorporated into the PCA model as predictors of pathological stage. The sensitivity and specificity of the PCA model in the test data set were 62.8% (95% CI 55.6% 68.1%) and 68.9% (95% CI 60.8% 76.0%), respectively. The positive and negative predictive values were 75.8% (95% CI 69.0% 81.6%) and 51.5% (95% CI 44.4% 58.5%), respectively. CONCLUSIONS The pre-cystectomy PCA model improved the ability to differentiate OC disease from extravesical BC and especially decreased the under-staging rate. The pre-cystectomy PCA model represented a user-friendly staging aid without the need for sophisticated statistical interpretation. KEYWORDS bladder cancer, pathological stage, decision support techniques, principal component analysis INTRODUCTION Bladder cancer (BC) is one of the most common cancers of the genitourinary tract with newly diagnosed patients expected in 2012 [1 ]. Radical cystectomy (RC) is considered the mainstay of treatment for patients with treatment-refractory non-muscle-invasive and muscle-invasive BC [2,3 ]. Nevertheless, the course of the disease is significantly different between organ-confined (OC) vs extravesical (EV) disease. The 5-year recurrence-free survival for OC disease is 89% and it drops down sharply to 62%, 50% and 35% for pt3b, pt4 and node positive tumours; respectively [4 ]. It has been shown that the subset of patients with EV disease would benefit most 2012 BJU INTERNATIONAL 111, E167 E172 doi: /j x x E167
2 AHMADI ET AL. from neoadjuvant chemotherapy (NAC) [5 ]. Conventional clinical staging of BC using bimanual examination, transurethral resection (TUR) of the tumour and CT scan with contrast agent, however, is not accurate in differentiating OC tumour from EV disease. The reported rate of postsurgical upstaging to EV disease is as high as 43% [ 6 ] and there is a need for additional methods to improve the accuracy of clinical staging. Decision aids, such as risk groupings, probability tables and nomograms, have greatly improved our ability to predict endpoints and provide patients with the data they require to make informed medical decisions [7 ]. The nomogram has been the most popular analytical model to predict recurrence, mortality and survival rates in BC [8 10 ]. Karakiewicz et al. [11 ] developed two nomograms to predict post-surgical T and N stages and showed an improvement, albeit suboptimal, in the accuracy of clinical stage to predict pathological stage. Principal component analysis (PCA) is a nonparametric statistical method of extracting relevant information from large data sets involving multiple variables [12 ]. It is a well established analytical method for prognostic stratification of patients with prostate cancer [13 ]. It is possible to condense several correlated variables into a single composite parameter by this method which facilitates prediction of dichotomous endpoints. This study evaluates the feasibility of the PCA method to develop a pre-cystectomy staging model incorporating demographic, clinical and biopsy-driven information from a large cohort of patients with clinical OC BC to predict post-surgical pathological stage. PATIENTS AND METHODS In a single-centre retrospective study, patients with clinical lymph node negative OC BC (clinical (c) T2bN0) and histology of urothelial carcinoma who underwent RC with intent to cure at the Institute of Urology, University of Southern California, between 1990 and 2008 were identified through our BC database. Demographics and clinical information including age, gender, clinical stage, number of intravesical therapies (IVnum), time between first diagnosis of muscle-invasive BC and RC, delivery of NAC, hydronephrosis and palpable mass were collected. In addition, TUR-driven information including grade, carcinoma in situ (CIS), lymphovascular invasion (LVI) and the number of tumours was recorded. Post-cystectomy pathological stage was converted to a dichotomous parameter including OC disease ( pt2n0) vs EV disease ( pt3 and/or ptanyn1 3) in all patients. Patients with a palpable mass fixed to surrounding structures were considered clinical T4 stage and were excluded from the analysis. To generate the PCA model, logistic regression analysis was initially performed to select the putative predictors of pathological stage for the final PCA model using all above-mentioned variables as covariates and post-surgical pathological stage as the endpoint variable. Patients were then randomly assigned into the training data set (two-thirds of the study population) to generate the PCA model and the test data set (one-third of the study population) to internally validate the model. PCA was run on the training data set in which putative predictors of pathological stage were assigned different weights in proportion to their relative contribution to the overall variance of the training data set (i.e. the larger the contribution of a particular variable to the overall variance, the higher its assigned weight) and the following formula was generated to calculate the cut-off point, termed the PCA score, in order to discriminate pathological OC from pathological EV disease: PCA score = W1 P1+ W2 P Wn Pn in which P1... P n are the variables incorporated into the model and W1... W n are the weights assigned by the algorithm. Values below the PCA score indicated pathological OC disease and values equal to or above that score specified pathological EV disease. The formula was then internally validated in the test data set. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for both training and test data sets were determined using a web calculator and the C-index value, derived from the PCA model, represented the predictive accuracy. In order to render the calculated predictive accuracy more representative of the real clinical setting, we set 65% as the lowest clinically accepted value for sensitivity of the model at the time of generating the C-index value. The institutional review board at our institute approved the study protocol and all patients signed and dated a consent form. Statistical analysis was done using SAS (SAS Institute, Cary, NC, USA) and P < 0.05 was considered statistically significant. RESULTS A total of 1186 patients were included in the study. The characteristics of the study population are summarized in Table 1. There was no significant difference in clinicodemographic characteristics and TUR-related features between patients in the training data set (790 patients) and in the test data set (396 patients). On surgical pathology, 685 patients (57.7%) had OC disease and 501 patients (42.1%) had EV disease including 237 patients (19.9%) with pt3an0 and 264 patients (22.2%) with nodal disease ( Table 2 ). Age, clinical stage, IVnum, LVI, multiple tumours, hydronephrosis and palpable mass as putative independent predictors of pathological stage (Table 3 ) were incorporated into the PCA model and the following formula was generated: PCA score = ( clinical stage) + ( age) ( IVnum) + ( LVI) + ( hydronephrosis) ( multiple tumours) + ( palpable mass) where clinical stage is ct0/cta/ctis = 0, ct1 = 1, ct2 = 2; age is chronological age in years rounded off to the closest discrete value; for LVI, absent = 0, present = 1; for hydronephrosis, absent = 0, present = 1; for tumour count, single = 0, multiple = 1; and for palpable mass, absent = 0, present = 1. Accordingly, age and clinical stage had the most and multiple tumours and palpable mass had least contribution to the final score. A cut-off value of 0.14 was calculated to discriminate OC BC from EV disease. Sensitivity, specificity, PPV and NPV as well as the C-index value of the PCA formula in the training and test data sets are presented in Table 4. Accordingly, the formula categorized 65.5% and 62.8% of patients correctly as OC BC and the probability of having pathological OC disease when the PCA score indicated OC disease was 61.9% and 51.5% in the training and test data sets, respectively. Regarding pathological EV disease, the formula correctly categorized E BJU INTERNATIONAL
3 PRE-CYSTECTOMY MODEL TO PREDICT PATHOLOGICAL STAGE TABLE 1 Baseline characteristics of study population Overall patients ( n = 1186) Training group ( n = 790) Validation group ( n = 396)P * Age 66.9 ± ± ± Gender (M/F) 930/ / / IV treatment Yes 376 (31.7) 235 (29.7) 141 (35.6) 0.07 No 810 (68.3) 555 (70.3) 255 (64.4) IVnum 0.6 ± ± ± Number of TURBT 2.0 ± ± ± TC time (months) 61 ± ± ± NAC Yes 50 (4.2) 33 (4.1) 17 (4.3) 0.9 No 1136 (95.8) 757 (95.9) 379 (95.7) Clinical stage T0 17 (1.4) 12 (1.6) 5 (1.2) 0.08 TIS/Ta 163 (13.7) 101 (12.8) 62 (15.6) T1 357 (30.1) 241 (30.5) 116 (29.3) T2 649 (54.7) 436 (55.1) 214 (53.9) Hydronephrosis Yes 216 (18.2) 144 (18.2) 72 (18.1) 0.9 No 970 (81.8) 646 (81.8) 324 (81.9) Palpable mass Yes 45 (3.8) 26 (3.3) 19 (4.8) 0.2 No 1141 (96.2) 764 (96.7) 377 (95.2) CIS Yes 358 (30.2) 236 (29.8) 122 (30.8) 0.7 No 828 (69.8) 554 (70.2) 274 (69.2) Multiple tumours 0.7 Yes 269 (22.6) 177 (22.4) 92 (23.2) No 917 (77.3) 613 (77.6) 304 (76.8) LVI Yes 191 (16.1) 139 (17.6) 52 (13.1) 0.09 No 995 (83.9) 651 (82.4) 344 (86.9) Tumour grade High 1038 (87.5) 705 (89.3) 333 (84) 0.1 Intermediate/low 148 (12.4) 85 (10.7) 63 (16) Pathological stage T0 95 (8.0) 55 (7.0) 38 (9.5) 0.6 TIS/Ta 199 (16.8) 127 (16.1) 68 (17.1) T1 201 (17.0) 117 (14.8) 67 (16.9) T2 266 (22.4) 141 (17.8) 72 (18.2) T3 341 (28.7) 132 (16.7) 57 (14.5) T4 84 (7.1) 33 (4.2) 15 (3.9) N (22.2) 185 (23.4) 79 (19.9) * P < 0.05 was statistically significant. Mean ± sd. Number (%). IV, intravesical; TC time, time interval from diagnosis to cystectomy; TURBT, transurethral resection of bladder tumour. 70.6% and 68.9% of patients with pathological EV disease as EV BC and the probability of having pathological EV BC when the PCA score indicated EV disease was 73.7% and 75.8% in the training and test data sets, respectively. DISCUSSION Clinical stage is an integral part of outlining treatment strategy and counselling patients with BC. The discordance rate between clinical stage and surgical stage, however, is currently undesirably high. The agreement rates between clinical stage and postsurgical pathological stage vary widely from 20% to 80% and, surprisingly, there has been a gradual increase in the rate of upstaging over time [6 ]. Shariat et al. [14 ] reported only 35.7% agreement between TUR stage and surgical stage in patients with BC. They reported pathological upstaging in 42% and pathological downstaging in 22% of their patients. The 5-year recurrence-free survival for OC disease is 89% and it drops sharply to 62%, 50% and 35% for pt3b, pt4 and node positive tumour, respectively [4 ]. In our experience, pathological upstaging to EV disease at cystectomy in patients with clinical OC BC was strongly associated with poor prognosis [15 ]. The upstaging rate from OC to EV disease is 36% 43% [ 6,14 ]. A recent European multi-institutional study showed that upstaging from OC to EV disease accounted for the major part (80%) of overall pathological upstaging in their study [16 ]. Data from US studies also showed 32% upstaging from TUR stage T2 or less to pt3 4 and/or pn1 3 stages at cystectomy [14 ]. In line with previous studies, the rate of upstaging from OC to EV and/or lymph node positive (LNP) BC was approximately 42% in our study which underscores the need for additional staging aids such as statistical predictive models. According to the results of the clinical trials performed on the role of NAC in muscleinvasive BC, all patients with local and advanced muscle-invasive BC (T2 T4) benefit from NAC. However, there is another common strategy to reserve NAC for more advanced stages ( T3) and treat patients with OC muscle-invasive BC, especially those with low risk disease without LVI or hydronephrosis, with RC and lymph node dissection since they show an excellent response to surgery alone [17 ]. An important feature of our PCA model was the significant decrement in clinical understaging rate (less than 25% pathological EV disease in the test set) compared with the reported rates by routine clinical staging alone (42.1% in our cohort and 36% 43% in the literature) which may also help in selection of candidates for NAC in the subset of patients with clinical OC BC but pathological advanced BC. Several clinicopathological factors are reportedly associated with post-surgical pathological stage. Turker et al. [16 ] reported 2012 BJU INTERNATIONAL E169
4 AHMADI ET AL. that clinical T2 stage, high grade tumour, LVI, female gender and histological variants were associated with a risk of upstaging from OC to EV disease. In addition, patients with preoperative hydronephrosis have 2.01 and 1.94 times higher risk of EV and LNP disease, respectively [18 ]. Using a multivariate model, we also showed that hydronephrosis was the most important predictor of pathological upstaging in invasive BC [15 ]. Karakiewicz et al. [11 ] performed the first modelling study on 726 patients and developed two nomograms to predict pathological EV and LNP disease. The T stage nomogram which consisted of age, TUR grade and CIS at TUR provided 4.0% 4.3% gain to the predictive accuracy of TUR stage alone (75.7% vs 71.4%) and the N stage nomogram which involved TUR stage and TUR grade provided 2.1% 2.3% gain to the predictive accuracy of TUR stage alone (63.1% vs 61.0%) [11 ]. In the present report, we give the results of the largest study on modelling approach to predict post-cystectomy pathological stage using clinical and biopsy-driven information. In comparison with previous studies, a large homogeneous group of patients as well as extensive pre-cystectomy variables were used to develop the model. We demonstrated that the PCA model including age, IVnum, LVI, hydronephrosis, multiplicity of tumours and palpable mass improved the staging accuracy of routine clinical stage. The use of prognostic and decision aids in urology, e.g. nomograms, look-up tables, risk grouping and artificial neural networks, has grown rapidly in the last decade [19 ]. We used a different multivariate statistical technique, termed PCA, to create our model in this study. PCA involves a mathematical variable reduction procedure that transforms several correlated variables into a smaller number of variables or into a single composite parameter (PCA score). The PCA algorithm is a well established analytical method in gene clustering [20 ], image analysis [21 ] and prognostic stratification of patients with prostate cancer [13 ]. We considered a relatively large number of pre-cystectomy variables (more than 14 variables) to develop our model and some of those factors are at least partially correlated in a clinical setting (i.e. IVnum with time from diagnosis to cystectomy; clinical stage with NAC and with palpable mass; CIS and LVI with history of intravesical chemotherapy); thus the PCA model is TABLE 2 Preoperative clinical stage breakdown stratified according to postoperative pathological stage Clinical Pathological stage stage PT0 PIS/Pa P1 P2a P2b P3a P3b P4a P4b Total CT CTIS/Ta CT CT2a CT2b Total TABLE 3 Predictive variables selected through stepwise logistic regression analysis and related weight calculated by PCA method Principal Stepwise logistic regression analysis component analysis Odds ratio (95% CI) P * Weight Age ( ) IVnum ( ) Clinical stage ( ) < LVI ( ) Multiple tumours ( ) Hydronephrosis ( ) < Palpable mass ( ) * P < 0.05 was statistically significant. Training set Test set Point est. (95% CI) Point est. (95% CI) Sensitivity 65.5 ( ) 62.8 ( ) Specificity 70.6 ( ) 68.9 ( ) PPV 73.7 ( ) 75.8 ( ) NPV 61.9 ( ) 51.5 ( ) C-index seemingly a suitable statistical technique to develop a predictive model in this setting. The PCA formula provides a suitable, coherent tool to predict post-surgical pathological stage without the need for statistical software for interpretation/ prediction. Despite the substantial decrease in pathological upstaging rate with PCA model, the sensitivity and NPV were only moderate. Predictive accuracy as indicated by the C-index value in this study was also moderate and at least 32% of patients were not accurately staged by the PCA formula. TABLE 4 Sensitivity, specificity, predictive values and area under the curve score of the PCA model to predict pathological OC BC in the training and test data sets Similarly, Karakiewicz et al. [11 ] stated that 24.3% and 36.7% of patients would still be misclassified with pt3 4 and pn1 3 nomograms, respectively. External validation of those nomograms in a multi-institutional study on 2477 patients also showed low staging accuracy of 67.5% for pathological T staging and 54.5% for pathological N staging, and both nomograms underestimated the real incidence of locally advanced BC [22 ]. Recent studies have shown that biological markers would significantly improve the predictive ability of staging models. Margel et al. [23,24 ] developed a PCA pre-cystectomy staging E BJU INTERNATIONAL
5 PRE-CYSTECTOMY MODEL TO PREDICT PATHOLOGICAL STAGE model using clinical information together with blood biomarkers including cancer antigen 125, carcinoembryonic antigen and carbohydrate antigen 19-9 and reported 85% accuracy in predicting EV BC. Lotan et al. [25 ] reported that the accuracy of the nomogram designed to predict recurrence in patients with non-muscle-invasive BC increased from 75% to 81% when nuclear protein matrix 22 was added to the model. Accordingly, we believe the current simple user-friendly PCA formula adds clinically important value to the predictive accuracy of clinical staging and is a useful decision aid to predict post-surgical pathological stage, especially pathological EV disease. However, like the two proposed nomograms, it has suboptimal accuracy and tissue-based or blood-based markers are apparently needed to optimize the predictive accuracy of the analytical model regardless of the quality and/or quantity of the involved clinical variables or the statistical method used to develop the model. The results of this study should be interpreted in the context of some limitations. As a tertiary referral centre, most of our patients had been referred from different community-based hospitals and urologists in private practice and most patients had their primary TUR performed at an outside hospital. The different quality of TURs reportedly leads to variation in clinical staging from 5% to 70% and may adversely affect the adequacy of biopsy specimens and the reproducibility of the current PCA staging model in other institutes. In addition, a different interpretation of histological findings on TUR specimens among pathologists may have an impact on the accuracy of TUR-related variables such as LVI. We tried to minimize this effect by doing re-tur for more recent patients and by re-reading of the TUR pathology slides by a dedicated genitourinary pathologist when the procedure was performed at an outside hospital. Palpable bladder mass is a relatively subjective finding which depends on several factors such as a patient s body habit. However, palpable mass had the lowest contribution to the PCA formula compared with other integrated variables and did not significantly affect the final PCA score. In conclusion, we generated and internally validated a pre-cystectomy PCA staging model involving clinicopathological information of a large cohort of patients and we were able to improve the ability of clinical stage to predict post-surgical pathological stage of BC. More importantly, this model enables urologists to avoid clinical under-staging. It is simple to use and does not need sophisticated statistical software for interpretation. The formula needs to be externally validated before routine application in clinical settings and incorporation of tissue-based and bloodbased biomarkers seems essential in order to enhance the accuracy of predictive staging models. ACKNOWLEDGEMENTS We thank Dr Eila Skinner for her intellectual contribution to the manuscript and Gus Miranda, project manager at USC Urology, for his collaboration on the study. CONFLICT OF INTEREST None declared. REFERENCES 1 American Cancer Society. Cancer Facts and Figures Atlanta : American Cancer Society, Stein JP. Indications for early cystectomy. Semin Urol Oncol 2000 ; 18 : Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol 2010 ; 22 : Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001 ; 19 : Sonpavde G, Sternberg CN. Neoadjuvant chemotherapy for invasive bladder cancer. Curr Urol Rep 2012 ; 13 : Svatek RS, Shariat SF, Novara G et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011 ; 107 : Nguyen CT, Stephenson AJ, Kattan MW. Are nomograms needed in the management of bladder cancer? Urol Oncol ; 28 : Karakiewicz PI, Shariat SF, Palapattu GS et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006 ; 176 (4 Pt 1 ): Zaak D, Burger M, Otto W et al. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int ; 106 : Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. Eur Urol 2008 ; 54 : Karakiewicz PI, Shariat SF, Palapattu GS et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006 ; 50 : Fukunaga K. Introduction to statistical pattern recognition. In Kaufmann M ed., Computer Science and Scientific Computing, 2nd edn. New York : Academic Press, 1990 : Potters L, Purrazzella R, Brustein S, Fearn P, Leibel SA, Kattan MW. A comprehensive and novel predictive modelling technique using detailed pathology factors in men with localized prostate carcinoma. Cancer 2002 ; 95 : Shariat SF, Palapattu GS, Karakiewicz PI et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007 ; 51 : Mitra AP, Skinner EC, Miranda G, Daneshmand S. A pre-cystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer. BJU Int 2012 ; [Epub ahead of print ]. DOI: /j X x 16 Turker P, Bostrom PJ, Wroclawski ML et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int 2012 ; 110 : Meeks JJ, Bellmunt J, Bochner BH et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012 ; 62 : Stimson CJ, Cookson MS, Barocas DA et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol ; 183 : Shabsigh A, Bochner BH. Use of nomograms as predictive tools in bladder cancer. World J Urol 2006 ; 24 : BJU INTERNATIONAL E171
6 AHMADI ET AL. 20 Shen YJ, Huang SG. Improve survival prediction using principal components of gene expression data. Genomics Proteomics Bioinformatics 2006 ; 4 : Bonifazzi C, Cinti MN, Vincentis GD et al. Principal component analysis of scintimammographic images. Phys Med 2006 ; 21 (Suppl. 1 ): May M, Burger M, Brookman-May S et al. [Validation of pre-cystectomy nomograms for the prediction of locally advanced urothelial bladder cancer in a multicentre study: are we able to adequately predict locally advanced tumour stages before surgery? ] Urologe A ; 50 : Margel D, Harel A, Yossepowitch O, Baniel J. A novel algorithm to improve pathologic stage prediction of clinically organ-confined muscle-invasive bladder cancer. Cancer 2009 ; 115 : Margel D, Bostrom P, Baniel J, Yossepowitch O, Zlotta A, Fleshner N. External validation of a biomarker based pre-cystectomy algorithm to predict nonorgan confined urothelial cancers. J Urol 2012 ; 187 : Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 2009 ; 103 : Correspondence: Siamak Daneshmand, USC Institute of Urology, Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 7416, Los Angeles, CA , USA. daneshma@med.usc.edu Abbreviations : BC, bladder cancer ; RC, radical cystectomy ; OC, organ-confined ; EV, extravesical ; NAC, neoadjuvant chemotherapy ; TUR, transurethral resection ; PCA, principal component analysis ; IVnum, number of intravesical therapies ; CIS, carcinoma in situ ; LVI, lymphovascular invasion ; PPV, positive predictive value ; NPV, negative predictive value ; LNP, lymph node positive. E BJU INTERNATIONAL
models; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns.
; 21 Urological Oncology MUSCULARIS PROPRIA AND UPSTAGING OF ct1 BLADDER CANCER BADALATO ET AL. BJUI Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect
More informationDiscovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy
Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy Anirban P. Mitra, M.D., Ph.D. Center for Personalized Medicine University of Southern California
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationAlicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationIncidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens
Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens Harman Maxim Bruins,* Hooman Djaladat,* Hamed Ahmadi, Andy
More informationTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Jeffrey M. Holzbeierlein, MD, FACS John W Weigel Professor & Chair Director of Urologic Oncology University of Kansas
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationConclusions. Keywords
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy Pascal Zehnder*, Urs E. Studer,
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More information1. Introduction. Correspondence should be addressed to Franklin C. Lee; Received 5 August 2013; Accepted 24 October 2013
Advances in Urology Volume 2013, Article ID 317190, 6 pages http://dx.doi.org/10.1155/2013/317190 Research Article Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin
More informationABSTRACT INTRODUCTION
/, 2017, Vol. 8, (No.51), pp: 89228-89235 Impact of preoperative diagnostic TURBT on progression-free survival in patients with pathological high-grade, stage T3/T4 bladder urothelial carcinoma Haichao
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationROBOTIC VS OPEN RADICAL CYSTECTOMY
ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationRefining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy
Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy Stephen H. Culp,*, Rian J. Dickstein,*, H. Barton Grossman, Shanna M. Pretzsch,* Sima Porten,* Siamak Daneshmand, Jie Cai,*
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationNeoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life.
THE INTERNATIONAL CONFERENCE PROGRESS IN URO-ONCOLOGY 5th Edition September, 25th 26th 2014 CLUJ-NAPOCA Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life. Dr.
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/96833
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationNomograms for Bladder Cancer
european urology 54 (2008) 41 53 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer Nomograms for Bladder Cancer Shahrokh F. Shariat a, *, Vitaly Margulis
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationImpact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationIncidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy
Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy Jacob T. Ark*, Kirk A. Keegan*, Daniel A. Barocas*, Todd M. Morgan*, Matthew J.
More informationClinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment
EUROPEAN UROLOGY 61 (2012) 237 242 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Bladder Cancer Editorial by Alexandre R. Zlotta on pp. 243 244 of this
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationBJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.
2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical
More informationDevelopment and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy
Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy Giuseppe Simone, Marco Bianchi, Diana Giannarelli, Siamak Daneshmand, Rocco
More informationThe Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma
Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell
More informationClinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationSystems Pathology in Prostate Cancer
Systems Pathology in Prostate Cancer Policy Number: 2.04.64 Last Review: 8/2014 Origination: 8/2010 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationKoji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
More informationInfluence of stage discrepancy on outcome in. in patients treated with radical cystectomy.
Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,
More informationA comparison of preliminary oncologic outcome and postoperative complications between patients undergoing either open or robotic radical cystectomy
ORIGINAL ARTICLE Vol. 42 (4): 663-670, July - August, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0393 A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationA Quality Improvement Project: Decreasing the Time from Diagnosis to Surgery in Patients with Bladder Cancer
Decreasing the Time from Diagnosis to Surgery in Patients with Bladder Cancer Abstract Otto Sandoval, M.D. 1 Andrew Blake 2 Josh Barnes- Livermore 3 Doug Salvador, M.D., MPH 4 Brian Jumper, M.D. 5 Jennifer
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationTCC recurrence within the upper tract urothelium following
Upper Tract Urothelial Recurrence Following Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: An Analysis of 1,069 Patients With 10-Year Followup Kristin M. Sanderson,* Jie Cai, Gustavo
More informationRadical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients
EUROPEAN UROLOGY 61 (2012) 1039 1047 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationEUROPEAN UROLOGY 60 (2011)
EUROPEAN UROLOGY 60 (2011) 946 952 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Bladder Cancer Editorial by Simon P. Kim and R. Jeffrey Karnes on pp. 953
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationBladder Sparing Treatment of Muscle Invasive Bladder Cancer
Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationORIGINAL ARTICLE. World J Urol (2011) 29: DOI /s
World J Urol (2011) 29:487 494 DOI 10.1007/s00345-011-0645-8 ORIGINAL ARTICLE Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationChemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008
Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Outcome of Open Radical Cystectomy and Ileal Conduit: A Single Center Experience Mahesh Kalloli
More informationHHS Public Access Author manuscript Clin Genitourin Cancer. Author manuscript; available in PMC 2017 August 01.
Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy Derek E. Thomas 1, Hristos Z. Kaimakliotis 1,2, Kevin R. Rice 1,2, Jose A. Pereira
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationDisclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
More informationExtranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis
EUROPEAN UROLOGY 64 (2013) 837 845 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationResearch Article Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
Advances in Urology Volume 14, Article ID 746298, 6 pages http://dx.doi.org/1.1155/14/746298 Research Article Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions N.
More informationDebate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer
Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University
More informationRole and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017
Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationPredictive value of pretreatment inflammationbased
Original Article - Urological Oncology Posted online 2015.11.3 pissn 2005-6737 eissn 2005-6745 Predictive value of pretreatment inflammationbased prognostic scores (neutrophil-tolymphocyte ratio, platelet-to-lymphocyte
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationA Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density
Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationAccepted for publication 12 August 2009 S.F.S. and G.G. are currently at Memorial Sloan-Kettering Cancer Center in New York, NY, USA
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology ASSOCIATION OF AGE WITH OUTCOMES OF UPPER TRACT UROTHELIAL CARCINOMA SHARIAT ET AL. BJUI BJU INTERNATIONAL Advanced patient age is associated
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationLymph node dissection: how much is enough?
1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationReviewer's report. Version:1Date:31 January Reviewer:IOANNIS LEOTSAKOS. Reviewer's report:
Reviewer's report Title:A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria
More informationSegmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer
Int Urol Nephrol (2014) 46:921 926 DOI 10.1007/s11255-013-0514-z UROLOGY - ORIGINAL PAPER Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter
More informationShould We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?
Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky Should We Screen? Prevalence 5 th most common cancer
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationEfficient and Effective Use of Exfoliative Markers
Innovations in Urologic Oncology: Bladder Cancer Efficient and Effective Use of Exfoliative Markers Jared M Whitson, MD April 9 th, 2010, CA URINARY TUMOR MARKERS Future Directions Urinary Tumor Markers
More informationUrothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis
Pathology Report With Squamous Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis Yunguang Liu, MD, PhD, Marilyn M. Bui, MD, and Bo Xu, MD, PhD Background: Squamous differentiation occurs
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationAs current clinical and pathological variables have a limited ability to predict tumour recurrence, progression or patient survival,
28 The Authors Mini-review Article PREDICTING SURVIVAL AFTER RADICAL CYSTECTOMY MARGULIS ET AL. BJUI BJU INTERNATIONAL Predicting survival after radical cystectomy for bladder cancer Vitaly Margulis, Yair
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationManagement options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center
Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th
More informationPartial Cystectomy for Invasive Bladder Cancer
European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen
More informationPreoperative risk factors for extraurothelial recurrence in N0M0 patients with renal pelvic cancer treated by radical nephroureterectomy
530 Preoperative risk factors for extraurothelial recurrence in N0M0 patients with renal pelvic cancer treated by radical nephroureterectomy KEIICHI ITO, JUNICHI ASAKUMA, KENJI KURODA, KAZUYOSHI TACHI,
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationDebate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.
Debate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.. Eighth European International Kidney Cancer Symposium Budapest 03-04 May 2013 The role of LND In organ confined
More informationUreteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes
ORIGINAL ARTICLE Vol. 43 (x): 2017 August 8.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2017.0218 Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes Muammer
More informationRAPN. in T1b Renal Masses? A. Mottrie. G. Denaeyer, P. Schatteman, G. Novara
RAPN in T1b Renal Masses? A. Mottrie G. Denaeyer, P. Schatteman, G. Novara Department of Urology O.L.V. Clinic Aalst OLV Vattikuti Robotic Surgery Institute Aalst Belgium Guidelines on Renal Cell Carcinoma
More information